Red X iconGreen tick iconYellow tick icon

George WigginsResearch Fellow

MSc, PhD (Otago)

Tel +64 364 0557

Research Interests

Dr George Wiggins is currently investigating the impact of germline copy number variation on endometrial cancer risk.

Otago Profile

George Wiggins in the lab_thumbnail
Skiing, socialising with work mates, and great research opportunities are all reasons George Wiggins recommends postgraduate study at the UOC.
See more…


Wiggins, G. (2023). Modifiers of BRCA1-associated breast cancer risk and potential preventative strategies [Invited]. Proceedings of the Genetics Otago (GO) Annual Symposium & Workshops. Retrieved from

Walker, L. C., de la Hoya, M., Wiggins, G. A. R., Lindy, A., Vincent, L. M., Parsons, M. T., … & ClinGen Sequence Variant Interpretation Working Group. (2023). Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup. American Journal of Human Genetics, 110(7), 1046-1067. doi: 10.1016/j.ajhg.2023.06.002

Hakkaart, C., Pearson, J. F., Marquart, L., Dennis, J., Wiggins, G. A. R., Barnes, D. R., Robinson, B. A., Mace, P. D., … Walker, L. C. (2022). Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. Communications Biology, 5, 1061. doi: 10.1038/s42003-022-03978-6

Crake, R. L. I., Burgess, E. R., Wiggins, G. A. R., Magon, N. J., Das, A. B., Vissers, M. C. M., Morrin, H. R., Royds, J. A., Slatter, T. L., Robinson, B. A., Phillips, E., & Dachs, G. U. (2022). Ascorbate content of clinical glioma tissues is related to tumour grade and to global levels of 5-hydroxymethyl cytosine. Scientific Reports, 12, 14845. doi: 10.1038/s41598-022-19032-8

Burgess, E. R., Crake, R. L. I., Phillips, E., Morrin, H. R., Royds, J. A., Slatter, T. L., Wiggins, G. A. R., Vissers, M. C. M., Robinson, B. A., & Dachs, G. U. (2022). Increased ascorbate content of glioblastoma is associated with a suppressed hypoxic response and improved patient survival. Frontiers in Oncology, 12, 829524. doi: 10.3389/fonc.2022.829524

Back to top